Improved glycaemic control of thrice-daily biphasic insulin aspart compared with twice-daily biphasic human insulin; a randomized, open-label trial in patients with type 1 or type 2 diabetes

Diabetes, Obesity and Metabolism

Volumn 10, Issue 3, 2008, Pages 229-237

  Clements, Michael R ^a   Tits, J ^b   Kinsley, B T ^c   Rastam J ^d   Friberg, H H ^d   Ligthelm, R J ^e  

^a WATFORD GENERAL HOSPITAL   (United Kingdom)

^b Ziekenhuizen Oost Limburg Campus AndréDumont ^*  (Belgium)

^c MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^d NOVO NORDISK A S   (Denmark)

^e Havenziekenhuis   (Netherlands)

Author keywords

Biphasic insulin aspart; Type 1 diabetes; Type 2 diabetes

Indexed keywords

BIPHASIC HUMAN INSULIN; BIPHASIC INSULIN; GLUCOSE; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN ASPART; ORAL ANTIDIABETIC AGENT; UNCLASSIFIED DRUG;

ADULT; ANGINA PECTORIS; ARTICLE; BODY MASS; BOLUS INJECTION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; FLU LIKE SYNDROME; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORNING DOSAGE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PARALLEL DESIGN; PATIENT COMPLIANCE; PATIENT SATISFACTION; PHARYNGITIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

EID: 39049163781     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2006.00687.x     Document Type: Article

References (23)

1. Bergenstal RM. Effective insulin therapy. In: De Fronzo RA, Ferrannini E, Keen H, Zimmet P eds. International Textbook of Diabetes Mellitus. Hoboken, NJ, USA: John Wiley & Sons, InH., 2004. Available at: http://www.mrw.interscience.wiley.com/itdm/articles/d0616/frame.html.
2. American Diabetes Association. Insulin administration (position statement). Diabetes Care 2003; 26: S121-S124.
3. Jorgensen LN, Nielsen FS. Timing of pre-meal insulins in diabetic patients on a multiple daily injection regimen. A questionnaire study. Diabetologia 1990; 33: A116.
4. Heinemann L. Do insulin-treated diabetic patients use an injection-meal-interval in daily life? Diabet Med 1995;12: 449-450.
5. Home PD, Barriocanal L, Lindholm A. Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers. Eur J Clin Pharmacol 1999; 55: 199-203.
6. Chapman TM, Noble S, Goa KL. Insulin aspart: A review of its use in the management of type 1 and 2 diabetes mellitus. Drugs 2002; 62: 1945-1981.
7. WHO. Diabetes mellitus: Report of a WHO study group. Geneva, World Health Organ Tech Rep Ser 1985; 727: 1-98.
8. Polonsky KS, Given BD, Van Cauter E. Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J Clin Invest 1988; 81: 442-448.
9. Ejskjaer N, Rasmussen M, Kamp N, Lindholm A, Christiansen JS. Comparison of thrice daily 'high' vs. 'medium' premixed insulin aspart with respect to evening and overnight glycaemic control in patients with type 2 diabetes. Diabetes Obes Metab 2003; 5: 438-445.
10. Gerich JE. Novel insulins: Expanding options in diabetes management. Am J Med 2002; 113: 308-316.
11. International Conference on Harmonisation (ICH) Topic E 6. Harmonised Tripartite Guideline for Good Clinical Practice. Step 5, Consolidated Guideline. 1-5-1996. www.ich.org.
12. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. Amended by the 48th General Assembly, Sommerset West, Republic of South Africa, October 1996. JAMA 1997; 277: 925-926.
13. Little RR. Glycated hemoglobin standardization -National Glycohemoglobin Standardization Program (NGSP) perspective. Clin Chem Lab Med 2003; 41: 1191-1198.
14. Bradley C. The diabetes treatment satisfaction questionnaire: DTSQ. In: Bradley C ed. Handbook of Psychology and Diabetes: A Guide to Psychological Measurement in Diabetes Research and Practice. Chur, Switzerland: Harwood Academic Publishers, 1994: 111.
15. Meadows KA, Abrams C, Sandbaek A. Adaptation of the Diabetes Health Profile (DHP-1) for use with patients with Type 2 diabetes mellitus: psychometric evaluation and cross-cultural comparison. Diabet Med 2000; 17: 572-580.
16. Meadows K, Steen N, McColl E et al. The Diabetes Health Profile (DHP): A new instrument for assessing the psychosocial profile of insulin requiring patients -development and psychometric evaluation. Qual Life Res 1996; 5: 242-254.
17. The DCCT Research Group. The absence of a glycemic threshold for the development of long-term complications: The perspective of the Diabetes Control and Complications Trial. Diabetes 1996; 45: 1289-1298.
18. Fleiss JL. Statistical Methods for Rates and Proportions. Hoboken, NJ, USA: Wiley, 1981: 1-321.
19. International Diabetes Federation (European Diabetes Policy Group). A desktop guide to type 2 diabetes mellitus. Diabet Med 1999; 16: 716-730.
20. American Diabetes Association. Standards of medical care in diabetes (position statement). Diabetes Care 2005; 28 (Suppl. 1): S4-S36.
21. Ligthelm RJ, Mouritzen U, Lynggaard H et al. Biphasic insulin aspart thrice daily is as efficacious as traditional basal bolus regimen with four daily injections in subjects with type 2 diabetes. Diabetes 2005; 54 (Suppl. 1): A122.
22. Christiansen JS, Parkner T, Dyrskog SEU et al. Clinical pharmacological aspects of Biphasic Insulin Aspart 50 and Biphasic Insulin Aspart 70 in non-obese and obese patients with type 2 diabetes. Diabetologia 2005; 48 (Suppl. 1): A838.
23. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.